Fake medicines are becoming a critical problem in Asia, constituting between 15 and 25% of the market in countries like India and Indonesia. Even highly regulated markets like Malaysia have a prevalence rate of around 5%, according to Ministry of Health studies. There is near consensus that concerted action is needed at the international and national level to solve this major threat to public health, with most commentary focusing on the lack of regulation in poor countries where the problem of fake medicines is most acute. Is regulation the answer, or are other mechanisms such as intellectual property rights and civil law more important.
Please visit EMHN for more information about the Emerging Markets Health Network